News
CHMP recommends approval of extension to indication of Cablivi for thrombotic thrombocytopenic purpura.- Ablynx
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Cablivi (caplacizumab-yhdp) from Ablynx. This extension requests that the drug be indicated for the treatment of adults and adolescents of 12 years of age and older weighing at least 40 kg experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.
Condition: Thrombotic Thrombocytopenic Purpura
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
4 mins